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Abstract
Background: Dysregulated signaling of the JAK/STAT pathway is a common feature of chronic myeloproliferative
neoplasms (MPN), usually associated with JAK2V617F mutation. Recent clinical trials with JAK2 inhibitors showed significant
improvements in splenomegaly and constitutional symptoms in patients with myelofibrosis but meaningful molecular
responses were not documented. Accordingly, there remains a need for exploring new treatment strategies of MPN. A
potential additional target for treatment is represented by the PI3K/AKT/mammalian target of rapamycin (mTOR) pathway
that has been found constitutively activated in MPN cells; proof-of-evidence of efficacy of the mTOR inhibitor RAD001 has
been obtained recently in a Phase I/II trial in patients with myelofibrosis. The aim of the study was to characterize the effects
in vitro of mTOR inhibitors, used alone and in combination with JAK2 inhibitors, against MPN cells.
Findings: Mouse and human JAK2V617F mutated cell lines and primary hematopoietic progenitors from MPN patients were
challenged with an allosteric (RAD001) and an ATP-competitive (PP242) mTOR inhibitor and two JAK2 inhibitors (AZD1480
and ruxolitinib). mTOR inhibitors effectively reduced proliferation and colony formation of cell lines through a slowed cell
division mediated by changes in cell cycle transition to the S-phase. mTOR inhibitors also impaired the proliferation and
prevented colony formation from MPN hematopoietic progenitors at doses significantly lower than healthy controls. JAK2
inhibitors produced similar antiproliferative effects in MPN cell lines and primary cells but were more potent inducers of
apoptosis, as also supported by differential effects on cyclinD1, PIM1 and BcLxL expression levels. Co-treatment of mTOR
inhibitor with JAK2 inhibitor resulted in synergistic activity against the proliferation of JAK2V617F mutated cell lines and
significantly reduced erythropoietin-independent colony growth in patients with polycythemia vera.
Conclusions/Significance: These findings support mTOR inhibitors as novel potential drugs for the treatment of MPN and
advocate for clinical trials exploiting the combination of mTOR and JAK2 inhibitor.
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Introduction
The chronic myeloproliferative neoplasms (MPN), which
include polycythemia vera (PV), essential thrombocythemia (ET)
and primary myelofibrosis (PMF) [1], are characterized by a
V617F point mutation in the exon 14 of Janus Kinase 2 (JAK2)
that occurs in 95% of PV and 60% of ET or PMF patients [2,3].
In addition, JAK2 exon 12 mutations are detected in 2–3% of PV
[4] and mutations in MPL, the receptor for thrombopoietin, have
been reported in 5–10% of ET and PMF patients [5–8]. These
molecular abnormalities result in a constitutive activation of the
JAK/signal transducer and activator of transcription (STAT)
signaling pathway and contribute to cytokine hypersensitivity and
cytokine independent growth of the mutant cells, as exemplified by
the erythropoietin-independent erythroid colonies (EEC) typically
found in most PV patients [9,10]. Transplant, transgenic and
conditional knock-in murine models have shown that expression of
mutated JAK2V617F is sufficient to recapitulate a MPN pheno-
type [11–19], indicating that constitutive activation of the JAK2/
STAT pathway deserves a central role in the pathogenesis of
MPNs.
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Therefore, activated JAK2 has become an attractive target for
therapy. In preclinical models, ATP-competitive JAK2 inhibitors
prevented the proliferation of JAK2V617F mutant cells in vitro and
mitigated myeloproliferation in JAK2V617F transgenic animals
[20,21]. When employed in clinical trials, JAK2 inhibitors
produced significant clinical improvement in patients with
myelofibrosis [22,23] or hydroxyurea-resistant PV or ET [24] at
such an extent that the JAK1 and JAK2 inhibitor ruxolitinib has
been approved recently by FDA for the treatment of patients with
intermediate and high risk myelofibrosis based on the results of
two large phase III trials [25,26] demonstrating rapid and
sustained reduction of splenomegaly and improvement of consti-
tutional symptoms. However, only modest reduction of the
JAK2V617F burden were documented [23]. This is consistent
with the observation that the disease-initiating cell population in
JAK2V617F knock-in mice was not affected by treatment with the
JAK2 inhibitor TG101348 [12], supporting current notion that
JAK2 mutation presumably does not represent the driver mutation
in MPN [2,27]. Thus, it seems unlikely that eradication of the
MPN clone can be achieved with (available) JAK2 inhibitors;
therefore, novel drugs and more effective therapeutic strategies
need to be sought. In this regard, it has been shown that co-
treatment of the HDACi panobinostat and the JAK2 inhibitor
TG101209 resulted in greater attenuation of JAK/STAT signal-
ing in human and mouse JAK2V617F-mutated cells and increased
cytotoxicity against MPN CD34+ cells compared to individual
drugs [28].
Enhanced activation of downstream pathways other than JAK/
STAT, including the phosphatidylinositol 3-kinase (PI3K) and
extracellular signal-regulated kinase (ERK) pathways, has been
documented in JAK2V617F mutated cells [29,30]. The serine/
threonine protein kinase B/Akt is downstream of PI3K [31]; it is a
key regulator of many cellular processes including cell survival,
proliferation and differentiation, and has been found dysregulated
in many cancer cells [32]. The main target of activated Akt is the
serine/threonine kinase mTOR that exists in two complexes,
TORC1 and TORC2. TORC1, formed with raptor, controls the
level of cap-dependent mRNA translation and phosphorylates
effectors such as the eukaryotic initiation factor 4E-binding protein
1 (4E-BP1) and S6 kinase 1 (S6K1); it is strongly inhibited by
rapamycin and its derivatives. In turn, phosphorylated 4E-BP1
affects the translation activation of several genes, including cyclin
D1, Bcl-2, Bcl-XL and VEGF, whereas S6K1 regulates cell growth
by phosphorylating key targets such as eukaryotic initiation factor
4E (eIF4E), mTOR itself and elongation-2 kinase. Both eIF4E and
S6K1 have been involved in cellular transformation and are
overexpressed in some poor-prognosis cancers [32,33]. Additional
components of mTORC1 include mammalian LST8/G-protein
b-subunit like protein (mLST8/GbL) and the recently identified
partners PRAS40 and DEPTOR [34,35]. mTOR also combines
with Rictor in mTORC2, that is largely rapamicin insensitive, and
is composed of GbL and mammalian stress-activated protein
kinase interacting protein 1 (mSIN1). mTORC 2 is also involved
in the phosphorylation of Akt at Ser473, that might, in some
instances, mediate a negative feedback loop to dampen IRS-1/
PI3K/AKT signalling. To overcome possible limitations and
drawbacks of allosteric mTOR inhibitors, such as rapamycin and
RAD001, novel molecules acting as competitive inhibitors of the
mTOR ATP active site have been developed; one of these, PP242
strongly suppresses both mTORC1 and mTORC2-mediated
activities [36] and exerted potent cytotoxicity against leukemia
cells [37].
Although Akt was found constitutively activate in JAK2V617F
mutated cells in vitro [29,30] and in V617F transgenic [38] or
knock-in mice [19], the contribution of PI3K/Akt signaling to the
pathogenesis of MPN is still poorly characterized. Akt is
phosphorylated and activated via PI3K in response to signals
originated by the erythropoietin (EPO) receptor; in particular, Akt
is able to support erythroid differentiation in JAK2-deficient fetal
liver progenitor cells through a mechanism downstream of EpoR
[39] and at least in part related to GATA-1 phosphorylation [40].
Akt resulted strongly activated in erythroblasts from the bone
marrow and the spleen of mice expressing a conditional
JAK2V617F knock-in allele, especially in V617F homozygous
animals [19]. Furthermore, phosphorylated STAT5 and Akt were
found expressedat high levels in the bone marrow of MPN
patients, particularly in megakaryocytes [41], consistent with the
strong inhibition of human megakaryocyte progenitors by
rapamycin [42]. Finally, inhibitors of the JAK/STAT and
PI3K/Akt pathway caused comparable inhibition of EEC
formation and EPO-induced erythroid differentiation in cultured
progenitor cells of patients with PV [43]. All this evidence is in
favor of abnormal Akt/mTOR signaling in MPN cells and
constitute the basis for exploring the potential effectiveness of
drugs targeting this pathway in MPN cells.
In this study we evaluated the effects of mTOR inhibitors, either
as single drugs or in combination with JAK2 inhibitors, in different
cellular models and primary cells from patients with MPN. We
present evidences that drugs targeting mTOR signaling exert
significant inhibition of MPN cells and their activity is synergis-
tically enhanced by co-treatment with a JAK2 inhibitor. There-
fore, these results reinforce the pathogenetic role of disregulated
Akt/mTOR pathway in MPNs and open new avenues for the
treatments of these disorders.
Materials and Methods
Reagents
RAD001 (a mTOR specific allosteric inhibitor with activity
against TORC1) was provided by Novartis (Basel, CH); PP242
[36] (an ATP domain inhibitor of mTOR, with activity against
TORC1 and TORC2) was obtained from Sigma-Aldrich (St.
Louis, Germany). The JAK1/JAK2 kinase ATP-competitive
inhibitors AZD1480 [44] and INC424 (ruxolitinib) were provided
by D. Huszar (AstraZeneca, Waltham, MA, USA) and T.
Radimeski (Novartis, Basel, CH), respectively. Antibodies against
phospho(P)-STAT5 (Tyr694), STAT5, P-4E-BP1 (Thr70), 4E-
BP1, P-JAK2 (Tyr1007/1008) and JAK2 were from Cell Signaling
Technology (Danvers, MA, US). Anti-human tubulin antibody
was from Santa Cruz Biotechnology (Santa Cruz, CA, US).
Recombinant growth factors were purchased from Miltenyi Biotec
(Gladbach, Germany).
Cell Lines and Cell Culture
The JAK2V617F mutated HEL and SET2 human cell lines
were purchased from the German Collection of Microorganisms
and Cell Cultures (DSMZ, Braunschweig, Germany). Murine Ba/
F3 and Ba/F3-EPOR cells expressing JAK2 wild-type (wt) or
JAK2V617F (VF) were donated by R. Skoda (University of Basel,
Switzerland) [45]. Cell lines were cultured in RPMI 1640
supplemented with 10% fetal bovine serum (FBS; Lonza, Belgium)
(20% for SET2 cells), antibiotics and L-glutamine. Recombinant
human EPO (rhEPO; Sigma) was added to JAK2 wt Ba/F3-
EPOR cells, that require the cytokine for survival and prolifera-
tion, at final concentration of 1 U/mL. This concentration was
chosen based on preliminary experiments showing that this
amount of cytokine, in addition to support cell proliferation and
survival ($90% of cells were routinely viable in the cultures),
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promoted phosphorylation of STAT5 at such an extent that was
very close to that measured in cultures of Ba/F3-EPOR VF cells
maintained in a cytokine-free medium (Figure S1).
Human Cells
Samples of peripheral blood or bone marrow were obtained
from patients diagnosed with PV or PMF (2008 WHO criteria)
[46] under a protocol approved by Institutional Review Board of
Azienda Ospedaliera-Universitaria Careggi and after obtaining a
written informed consent; CD34+ cells were immunomagnetically
selected as described [47]. Control CD34+ cells were obtained
from discarded cord blood units. Research was carried out
according to the principles of Declaration of Helsinki.
Inhibition of Proliferation Assay, Clonogenic Assay, and
Apoptosis or Cell Cycle Analysis
Ba/F3-EPOR cells, both wt and VF, HEL and SET2 cells were
plated at 26104 in 96-well culture tissue plates with increasing
concentrations of the drug(s), in triplicate, and the amount of
viable cells was assessed at 48 h using the WST-1 assay (Roche,
USA) after normalization to wells containing an equivalent volume
of vehicle (DMSO) only. For clonogenic assay, 56103 cells were
plated in 0.5% agar in medium supplemented with 10% FBS (plus
1 U/mL EPO in case of Ba/F3-EPOR wt cells); variable amount
of the drug(s) (or an equivalent volume of vehicle in control plates)
was added once at the beginning of culture. Colonies were
enumerated by inverted microscopy after 7 day incubation, in
duplicate. Quantification of apoptotic cells was accomplished by
flow cytometry using the Annexin-V-FLUOS Staining kit (Roche);
at least 20,000 events were acquired. For cell cycle distribution
analysis by flow cytometry, 16106 cells were treated with ethanol
95%, RNase 10 mg/mL and propidium iodide 50 mg/mL.
The concentration at which 50% inhibition (IC50) of cell
proliferation or colony formation, promotion of apoptosis or
change in distribution of the cells in cell cycle phase occurred was
calculated using the Origin software (v7.5, OriginLab, North-
ampton, MA). In experiments where two drugs were concurrently
administered, the combination index (CI), that is a measure of the
interaction between two drugs, was calculated according to the
median-effect principle of the Chou and Talalay method [48]
using the CalcuSyn software (Biosoft Cambridge, UK). According
to this formula, with CI,1 the interaction of two drugs is
considered synergistic, when CI= 1 the interaction is additive, and
when CI.1 the interaction is antagonistic [48].
Colony Assay for Human Hematopoietic Progenitors and
CD34+ Proliferation Assay
Bone marrow mononuclear cells from MPN patients or control
subjects were plated at 16105/mL in methylcellulose (MethoCult;
StemCell Technologies, Vancouver, Canada) supplemented with
SCF 50 ng/mL, IL-3 10 ng/mL, IL-6 10 ng/mL, GM-CSF
10 ng/mL, G-CSF 10 ng/mL and EPO 1 U/mL for the growth
of BFU-E and CFU-GM. For the growth of CFU-Mk, 56104/mL
CD34+ cells were plated in a 24-well plate in Megacult Collagen
and medium with lipids (StemCell Technol.) supplemented with
Thrombopoietin 50 ng/mL, IL-3 10 ng/mL, IL-6 10 ng/mL.
Colonies were enumerated on day 14 according to standard
criteria. EEC assay was performed by plating 2.56105/mL
peripheral blood mononuclear cells from PV patients in methyl-
cellulose containing leukocyte-conditioned medium without EPO
(StemCell Technol., cat. No.#04531); hemoglobinized colonies
were scored at 10 days.
To measure the drug-induced inhibition of CD34+ cell growth,
purified cells were plated at 3?104 cells/well in IDMEM
supplemented with cytokines and variable amounts of the drugs
were added. Cell proliferation was evaluated using the WST-1
Assay (Roche, USA) after 48 h and results were normalized to
wells containing vehicle only.
SDS-PAGE Western Blotting
Cells were resuspended in RIPA lysis buffer (50 mM pH 7.4
Tris-HCl, 150 mM NaCl, 1% NP-40, 1 mMEDTA) containing a
proteinase inhibitor cocktail (Halt Protease Inhibitor Cocktail Kit,
PIERCE, Rockford, IL, US) and subjected to sodium dodecyl
sulphate polyacrylamide gel electrophoresis separation and west-
ern blotting onto Immunoblot PVDF membrane (BioRad,
Hercules, CA, US), according to standard protocols. Membranes
were probed with primary antibodies followed by horseradish
peroxidase-conjugated anti-Ig antibody produced in rabbits
(Sigma-Aldrich); immunoreactive proteins were revealed with
ECL using the Image Quant 350 apparatus (GE Healthcare, Little
Chalfont, UK).
RNA Isolation and Real-Time Quantitative PCR (RTQ-PCR)
Total RNA was purified using Trizol (Invitrogen-Life Technol-
ogies, Paisley, UK), and the RNA concentration and purity/
integrity was determined with NanoDrop ND-1000 spectropho-
tometer (NanoDrop Techn., Wilmington, DE, USA). One
microgram of RNA was reverse transcribed using High Capacity
cDNA Archive Kit (Applied Biosystems, Foster City, CA). RT-
QPCR reactions were performed with the TaqMan Universal
PCR Master Mix using ABI PRISM 7300 HT and TaqManH
Gene Expression Assays (Applied Biosystems), in triplicate. Gene
expression profiling was achieved using the Comparative cycle
threshold (CT) method of relative quantitation using VIC-labeled
RNaseP probe as the housekeeping gene (DCT).
Figure 1. Inhibition of cell proliferation and colony formation of wild-type (wt) and JAK2V617F (VF)-expressing Ba/F3-EPOR cells by
mTOR and JAK2 inhibitors. Results of short-term proliferation assay (panel A) and clonogenic assay (panel B) are shown. Values represent the
percent inhibition compared to control wells containing vehicle only. Data shown are the mean of at least five (panel A) and three (panel B)
independent experiments. Individual IC50 values are reported in the Results section.
doi:10.1371/journal.pone.0054826.g001
Table 1. Effects of mTOR (RAD001 and PP242) and JAK2
(Ruxolitinib and AZD1480) inhibitors on the proliferation rate
and clonogenic growth of human JAK2V617F mutated cell
lines.
IC50 (mM)
RAD001 PP242 AZD1480 Ruxolitinib
Proliferation assay
HEL 1462.8 1.560.1** 0.8660.02** 0.7960.15**
SET2 17.060.3 0.2860.01 0.0960.005** 0.1660.02**
Clonogenic assay
HEL 0.9360.01** 0.17260.059** 0.4660.03** 0.3760.177**
SET2 0.04460.015** 0.06260.019** 0.03560.01** 0.02760.009**
doi:10.1371/journal.pone.0054826.t001
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Statistical Methods
Comparison between groups was performed by the Mann-
Whitney U or Fisher test as appropriate, using the SPSS (StatSoft,
Inc., Tulsa, OK) or Origin software. The level of significance from
two-sided tests was P,0.05.
Results
Inhibition of mTOR Signaling Results in Reduced
Proliferation and Impaired Colony Formation of
JAK2V617F Mutant Cell Lines
To ascertain the effects of mTOR inhibition on the growth of
cell lines harboring the JAK2V617F mutation we employed the
selective allosteric mTOR inhibitor RAD001 and the ATP
competitive inhibitor of the active site of mTOR, PP242.
Concurrently, we used the two ATP-competitive JAK2 inhibitors
ruxolitinib and AZD1480. JAK2 wt Ba/F3 cells engineered to
express the erythropoietin receptor (Ba/F3-EPOR wt) and the
cytokine-independent counterpart with ectopic expression of
JAK2V617F (Ba/F3-EPOR VF) were exposed to increasing drug
concentrations in proliferation (48 h; Figure 1A) and clonogenic (7
days; Figure 1B) assay. We found that Ba/F3-EPOR VF cells were
definitely more sensitive to inhibition of the mTOR pathway than
the wt counterpart: the IC50 (mean6SD) was 651650 nM versus
11,00061,000 nM and 5006100 nM versus 5,93161,000 nM,
respectively, in case of RAD001 and PP242 (P,0.001 for both)
(Figure 1A). Similarly, JAK2 inhibitors effectively prevented the
growth of Ba/F3 VF cells with greater sensitivity compared to wt
cells; the IC50 was 313623 nM versus 752630 nM and
220620 nM versus 457615 nM in case of AZD1480 and
Ruxolitinib, respectively (P,0.001 for both) (Figure 1A). Also
the clonogenic potential of Ba/F3-EPOR VF cells, evaluated in
semisolid cultures, was potently inhibited by mTOR and JAK2
inhibitors at very low nanomolar concentrations, as shown in
Figure 2. Inhibition of proliferation of CD34+ cells from PMF patients by mTOR and JAK2 inhibitors. CD34+ cells from patients with PMF
(n = 6) or control subjects (Ctr; n = 5) were plated at 26105/mL in 96-well culture tissue plates with increasing concentrations of the drugs, in triplicate;
viable cells were assessed after 48 hrs using the WST-1 assay and normalized to wells containing an equivalent volume of vehicle (DMSO) only. Values
shown are the mean6SD The concentration at which 50% inhibition of proliferation occurred (IC50) was calculated (see Results section for details).
doi:10.1371/journal.pone.0054826.g002
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Figure 1B. The IC50 for VF and wt Ba/F3-EPOR cells was
462 nM versus 22610 nM and 47612 nM versus 3086100 nM
for RAD001 and PP242, respectively, and 19611 nM versus
7506100 nM and 20615 nM versus 7406100 nM for AZD480
and ruxolitinib, respectively (P,0.01 for all combinations). Similar
results were obtained using the parental IL-3- dependent Ba/F3
JAK2 wt and VF cell lines (not shown). Finally, we tested the effect
of different inhibitors also in liquid cultures of cytokine-indepen-
dent Ba/F3 VF cells maintained in the presence of Epo (1 U/mL).
We found that the IC50 remained significantly lower
(1,2316100 nM for RAD001 and 7506100 nM for PP242) than
wt cells (11,00061,000 nM and 5,93161,000 nM, respectively;
P,0.01), reinforcing the greater sensitivity of VF cells to mTOR
inhibitors. On the other hand, the addition of Epo largely
prevented the inhibitory effects of JAK2 inhibitors: the resulting
IC50 was 707611 nM for AZD1480 and 521645 nM for
ruxolitinib compared with 752630 nM and 457615 nM, respec-
tively, in wt cells.
We then evaluated the effect of increasing drug amounts on the
rate of cell division through the analysis of changes in cell cycle of
Ba/F3-EPOR VF cells that could contribute to slowed cell division
observed in previous experiments (Figure S2A). After 24 hours,
mTOR and JAK2 inhibitors induced a block in the G0/G1 phase
with subsequent decrease in the S-phase: a 50% reduction of the
cells in the S-phase compared to untreated cells was reached at a
median value of 6.5 mM for RAD001, 1.87 mM for PP242,
1.2 mM for AZD1480 and 1.87 mM for Ruxolitinib. On the other
hand, the proportion of Annexin V positive apoptotic cells
increased dose-dependently with PP242 and both the JAK2
inhibitors: the median IC50 values for apoptosis were 4.0 mM for
PP242, 0.8 mM for AZD1480 and 1.3 mM for Ruxolitinib (Figure
S2B). In cells exposed to RAD001 an increase of apoptotic cells
became appreciable only at drug concentrations .3.3 mM
followed by a plateau, resulting in an IC50 value of 5.0 mM,
indicating modest efficacy of RAD001 as inducer of cell apoptosis.
Efficacy of the drugs was also assessed in the human
JAK2V617F mutated HEL and SET2 cell lines. We found that
both cells lines were relatively insensitive to RAD001 showing an
IC50 in the micromolar range (mean value, 14.0 mM and 17.0 mM,
respectively for HEL and SET2 cells), unlike the case of PP242
and JAK2 inhibitors that efficaciously prevented cell proliferation
at nanomolar concentration (see Table 1). On the other hand,
counterintuitively, colony formation by HEL and SET2 cells was
efficaciously prevented at nanomolar concentrations of RAD001
(mean value, 0.93 nM and 0.044 nM for HEL and SET2 cells,
respectively) and PP242 (0.172 nM and 0.062 nM), and similar for
JAK2 inhibitor AZD1480 (0.46 nM and 0.035 nM) and Rux-
olitinib (0.37 nM and 0.027 nM) (Table 1). We are not able to
provide obvious explanations for such contrasting findings
concerning the efficacy of RAD001 in clonogenic versus prolifer-
ation assay, that could not be actually ascribed to different culture
conditions, variable times of drug exposure, types of plastics used
as well as a number of other variables we deliberately introduced
in the system. One possibility might be that optimal inhibition of
HEL and SET2 cell proliferation by RAD001 requires some kind
of cell-to-cell interactions that are favoured in the semisolid media
as compared with liquid cultures. These experiments also
indicated that HEL cells, that display multiple copies of
JAK2V617F, resulted significantly less sensitive than the
JAK2V617F heterozygous SET2 cells.
In further experiments aimed at evaluating the effects of
treatment on cell cycle and apoptosis we used SET2 cells as a
model. Mirroring the results obtained in Ba/F-EPOR VF cells, we
observed a dose-dependent decrease of SET2 cells in the S-phase
due to a block in G0/G1: a 50% reduction of SET2 cells in the S-
phase compared to controls was obtained with a median
concentration of 33 mM for RAD001, 2.7 mM for PP242,
1.5 mM for AZD1480 and 10 mM for Ruxolitinib. Apoptosis was
promoted more efficaciously by JAK2 inhibitors (median IC50
values for apoptosis were 0.4 mM for AZD1480 and 0.5 mM for
Ruxolitinib) than RAD001 (38 mM) and PP242 (5.2 mM) (data not
shown in detail).
Inhibition of the mTOR- and JAK2-dependent signalling
pathways in Ba/F3-EPOR and SET2 cells exposed to the relevant
drugs was supported by results of western blot experiments
showing reduced levels of phosphorylated 4eBP1, in case of
mTOR inhibitors, and phosphorylated JAK2 and STAT5 in case
of JAK2 inhibitors (Figure S3A, B). We also assayed the mRNA
level of selected downstream targets in SET2 cells We found that
mTOR and JAK2 inhibitors similarly induced statistically
significant early downregulation of CCND1, that however resulted
more durable (at 24 h) with JAK2 inhibitors. On the other hand,
JAK2 inhibitors only caused a statistically significant downregu-
lation of antiapoptotic genes such as PIM1 and BCLXL (Figure S4).
As a whole, these data indicate that blocking mTOR signalling
pathway is effective in reducing proliferation and clonogenic
potential of cells expressing the JAK2V617F mutation; however,
mTOR inhibitors appeared to exert mainly a cytostatic rather
than an apoptotic effect when compared with JAK2 inhibitors.
mTOR Inhibitors Impair the Proliferation and Clonogenic
Potential of CD34+ Cells from MPN Patients
To exploit whether the proliferation of primary MPN cells could
be similarly affected by mTOR inhibitors, we incubated CD34+
cells from PMF patients and healthy controls (n = 6 and n= 5,
respectively) with increasing concentration of RAD001 and
PP242, and measured the proportion of viable cells relative to
control wells containing vehicle only; an optimized cytokine
cocktail was added to both patients’ and controls’ wells to allow
Table 2. Activity of mTOR (RAD001 and PP242) and JAK2
(Ruxolitinib and AZD1480) inhibitors on the clonogenic
potential of hematopoietic progenitors from patients with PV
and PMF (n = 10 each) and healthy controls (n = 10).
IC50 (nM)
RAD001 PP242 AZD1480 Ruxolitinib
BFU-E
Ctrl 432622 233650 226617 167670
PV 91615** 58618* 135619** 2767*
MF 42610** 3868* 2768** 46610*
CFU-GM
Ctrl 335616 148640 193613 209640
PV 7564 ** 31615* 4665** 3966*
MF 46613** 46620* 963** 4364*
CFU-Mk
Ctrl 572613 1362 400612 1265
PV 5065** 361** 4462** 462*
MF 4465** 2562 ** 5963** 463*
The IC50 was calculated using data derived from the sensitivity curves to drugs
reported in Figure 3. *, P,0.05, **, P,0.01.
doi:10.1371/journal.pone.0054826.t002
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cell survival. As shown in Figure 2, the proliferation of PMF
CD34+ cells was inhibited at significantly lower concentration of
RAD001 (IC50 = 2716100 nM) and PP242 (IC50 8006200 nM)
compared to healthy subjects (IC50 =.5,000 nM and
2,90061,000 nM, respectively (P,0.01 for both). Similarly
AZD1480 and ruxolitinib produced more effective inhibition of
the proliferation rate of CD34+ cells from PMF patients
(IC50 = 474630 nM and 8406300 nM, respectively) compared
to control cells (IC50 = 8916100 nM and .5,000 nM; P,0.05
and 0.001, respectively).
Then, to evaluate the effects of mTOR inhibitors on the colony-
forming activity of hematopoietic progenitors from MPN patients,
bone marrow mononuclear cells or CD34+ cells from PMF and
PV patients and healthy controls were cultured in the presence of
cytokines optimally supporting the growth of BFU-E, CFU-G/
GM or CFU-Mk. A separate set of experiments was also devised to
evaluate drugs’ effect on the formation of erythropoietin endog-
enous erythroid colonies (EEC) in patients with PV. Drugs were
added at increasing concentrations once at the beginning of
culture and the IC50 was established by comparison to control
Figure 3. mTOR and JAK2 inhibitors preferentially suppress colony formation from hematopoietic progenitors of MPN patients as
compared to healthy controls. Mononuclear cells from patients with PV or PMF (n = 10 each) or control subjects (n = 10) were plated at 105/mL in
cytokine-supplemented methylcellulose medium for the growth of erythroid burst-forming unit (BFU-E) and granulocyte-macrophage colony-
forming unit (CFU-GM), and CD34+ cells (56104/mL) were plated in collagen-based medium for megakaryocyte colony-forming unit (CFU-Mk).
Increasing amounts of mTOR inhibitors (RAD001 and PP242) or JAK2 inhibitors (AZD1480 and Ruxolitinib) were added at the beginning of culture.
Colonies were enumerated on day 14 and expressed as a percentage of the colonies grown in control plates containing vehicle only.
doi:10.1371/journal.pone.0054826.g003
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dishes containing vehicle only. As shown in Figure 3, colony
formation from MPN patients was dose-dependently reduced by
mTOR inhibitors; the data reported in Table 2 indicate that MPN
progenitor growth could be inhibited with IC50 drug concentra-
tion significantly lower than control cells (in case of RAD001, from
4.7 to 13-fold lower and in case of PP242 from 2.6 to 6.1-fold
lower, depending on colony type), pointing to a substantial degree
of drug selectivity against MPN cells. Progenitors forming
megakaryocytic colonies were the most sensitive. Results obtained
with JAK2 inhibitors were similar, with IC50 values lower than
control of 1.6–21.4-fold in case of AZD1480 and 3–6.2-fold in case
of Ruxolitinib. By keeping separate JAK2V617F positive and
negative PMF subjects (n = 5 each) we did not observe appreciable
difference in the inhibitory effect of either drugs depending on the
JAK2 mutation status of the patients (not shown in detail). Finally,
we determined that the growth of EEC from circulating
progenitors in PV patients (n = 5) could be inhibited at very low
nanomolar concentrations of RAD001 (IC50 = 15.0610.0 nM),
Table 3. Combining mTOR and JAK2 inhibitor resulted in synergistic inhibition of the proliferation rate (A) and clonogenic
potential (B) of Ba/F3-EPOR VF and SET2 cells.
Single drug Drug combination
IC50 (nM) IC50 (nM) CI index
Ba/F3-EPOR VF
RAD001 AZD1480 RAD001 AZD1480
651650 313623 121639 58619 0.5±0.1
RAD001 Ruxolitinib RAD001 Ruxolitinib
651650 220620 304683 72624 0.3±0.1
PP242 AZD1480 PP242 AZD1480
5006100 313623 212618 164632 0.5±0.2
PP242 Ruxolitinib PP242 Ruxolitinib
5006100 220620 2656190 94638 0.79±0.3
SET2
RAD001 AZD1480 RAD001 AZD1480
17,00063,000 9065 1,798687 9.560.4 0.48±0.05
RAD001 Ruxolitinib RAD001 Ruxolitinib
17,00063,000 160624 1,59761,000 53635 0.66±0.05
PP242 AZD1480 PP242 AZD1480
285611 9065 122622 29626 0.56±0.1
PP242 Ruxolitinib PP242 Ruxolitinib
285611 160624 36632 31621 0.27±0.2
Ba/F3-EPOR VF
RAD001 AZD1480 RAD001 AZD1480
462 19611 0.960.4 4.362.2 0.4±0.3
RAD001 Ruxolitinib RAD001 Ruxolitinib
462 20615 1.160.2 5.961.9 0.6±0.3
PP242 AZD1480 PP242 AZD1480
5006100 19611 1664 6.561.8 0.8±0.2
PP242 Ruxolitinib PP242 Ruxolitinib
5006100 20615 6.265 2.762 0.24±0.2
SET2
RAD001 AZD1480 RAD001 AZD1480
44615 35610 5.264 4.163 0.23±0.1
RAD001 Ruxolitinib RAD001 Ruxolitinib
44615 2769 6.261 3.760.4 0.32±0.04
PP242 AZD1480 PP242 AZD1480
62619 35610 1664 160.5 0.4±0.05
PP242 Ruxolitinib PP242 Ruxolitinib
62619 2769 29616 12.867 0.9±0.13
Data shown (mean 6 SD) are from at least two experiments. The Combination Index (CI) was calculated as described in Materials and Methods. A CI,1 indicates that
the interaction of the two drugs is synergistic. The first two columns report, for convenience, the IC50 value of the individual drugs in these experimental settings (see
Results section for details).
doi:10.1371/journal.pone.0054826.t003
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PP242 (IC50 = 1.060.7 nM), AZD1480 (IC50 = 19.062.0 nM)
and Ruxolitinib (IC50 = 1.861.0 nM), indicating a high sensitivity
of these progenitors, that are considered as being mostly
JAK2V617 mutated [10,49], to both mTOR and JAK2 inhibitors.
In aggregate, these data indicate that colony growth from
hematopoietic progenitors of MPN patients can be efficiently and
selectively inhibited by mTOR inhibitors compared to controls.
Combination of mTOR and JAK2 Inhibitor Results in
Improved Efficacy Against MPN Cells
Next, we evaluated the effects of concurrent inhibition of
mTOR and JAK2 signaling in Ba/F3-EPOR VF and SET2 cells.
Cells were put in culture using progressively increasing concen-
trations of the drugs and the proportion of viable cells at 48 h, or
the number of colony formed at 10d, was measured; the
combination index (CI), as a measure of the interaction between
two drugs, was calculated as detailed in the Methods section
(examples are shown in Figure S5 and 6). Results presented in
Table 3 indicate that combination of a mTOR and JAK2 inhibitor
resulted in markedly lower concentrations of the individual drugs
necessary to produce a 50% inhibition in the assay. For example,
the proliferation of SET2 cells could be efficaciously inhibited with
RAD001 amounts of 9.4 to 10.6-fold lower, 2.3 to 7.9-fold in case
of PP242, 3.1 to 9.4-fold in case of AZD1480 and 3.0 to 5.1-fold in
case of Ruxolitinib, depending on the drug combinations. The
calculated CI values was always lower than 1, ranging from 0.33 to
0.98, to indicate synergism of the mTOR and JAK2 inhibitors in
the two cell lines and experimental settings.
We finally assessed the efficacy of combining mTOR and JAK2
inhibitor in preventing the generation of EEC from peripheral
blood mononuclear cells of PV patients. As reported in Table 4,
the concentration of mTOR and JAK2 inhibitors required to
produce a 50% inhibition of EEC were reduced, as compared to
each drug alone, of 5.2 to 7.9-fold in case of RAD001, 2.5 to 6.2-
fold in case of PP242, 7.6 to 27-fold in case of AZD1480 and 6 to
9-fold in case of Ruxolitinib. The calculated CI ranged from 0.13
to 0.63.
Therefore, these results strongly support synergism of mTOR
and JAK2 inhibitors in inhibiting the growth of MPN cells.
Discussion
Dysregulation of the JAK2/STAT pathway represents a central
mechanism in the pathogenesis of MPNs: in fact, (i) the
JAK2V617F gain-of-function mutation occurs in the majority of
patients with PV and 60% of PMF and essential thrombocythemia
[2,3], (ii) other mutations (MPL, LNK, CBL) found in 5–10% can
similarly activate the JAK/STAT pathway [5–8,50], (iii) mouse
models indicate that those mutations are able to induce a
myeloproliferative disorder [11–19], (iv) the JAK/STAT pathway
is involved in the dysregulated cytokine expression that accompa-
nies MPNs and underlies some tract of the clinical phenotype [51],
and finally (v) targeting activated JAK2 with ATP-competitive
JAK2 inhibitors resulted in measurable clinical improvements in
patients with myelofibrosis [25,26]. The clinical efficacy of JAK2
inhibitors has been ascribed to a variable degree of myelosup-
pression and a general down-regulation of inflammatory cytokine
signalling (at least in part mediated by the concomitant anti-JAK1
properties of some JAK2 inhibitors such as ruxolitinib) [52], well
keeping in mind that none of the available molecules is specific to
mutant as opposed to wild-type JAK2. Conceivably, in contrast to
the capacity of JAK2 inhibitors to reduce the enlarged spleen and
improve disease symptomatic manifestations, changes in the
burden of mutated cells have been variable (with SAR302503
being reported as the most effective until now [53]) but usually
modest, at least in the short-term follow-up. Also, while generally
well tolerated, JAK2 inhibitors caused some degree of unwanted
myelosuppression, particularly anemia and thrombocytopenia.
Therefore, current efforts are directed towards additional targets
involved in the dysregulated proliferation of MPN cells and/or
novel therapeutic options with the hope to maximize anticancer
efficacy and/or improve the tolerability profile of available JAK2
inhibitors.
In this study we have focused on the mammalian target of
rapamycin (mTOR), a key downstream target of the PI3K/Akt
pathway, with the objective to characterize the efficacy of mTOR
inhibitors in different cellular models of MPNs, including primary
cells. We found that JAK2V617F mutated human and murine
leukemia cell lines are sensitive to mTOR inhibitors showing a
dose-dependent inhibition of cell proliferation and clonogenic
potential that mainly reflected a cytostatic rather than an apoptotic
effect. However, the ATP mimetic inhibitor PP242 resulted a
more potent and dose-dependent inducer of apoptosis than the
allosteric inhibitor RAD001, leading to speculate that such a
difference may be attributable to the activity of PP242 against both
mTORC complexes as opposed to the inhibition of mTORC1
only exerted by RAD001 [31]; further experiments are in progress
at this regard. We also showed that mTOR inhibitors inhibited the
proliferation of CD34+ cells and hematopoietic colony formation
from MPN patients at doses significantly lower than healthy
subjects and potently reduced the generation of erythroid-
independent colonies (EEC) that are considered to closely
represent the MPN clone since they are mostly JAK2V617F
mutated [10,49]. As a whole, these results, indicating sensitivity of
MPN cells to mTOR inhibitors, provided mechanistic explanation
for the findings of a phase I/II trial that showed efficacy of
RAD001 (Everolimus) against splenomegaly and symptomatic
burden in patients with myelofibrosis [54] and reinforce the
rationale for designing clinical trials with novel, and possibly more
effective, drugs targeting the activated PI3K/Akt/mTOR path-
way.
In fact, the abnormal activation of mTOR in cancer cells and its
role in many critical cellular processes, together with the
availability of a growing number of molecules entering the clinical
Table 4. Combination of mTOR and JAK2 inhibitor resulted
synergistic in reducing erythropoietin-independent colony
formation in primary cells from PV patients.
Drug combination
IC50 (nM) IC50 (nM) CI index
RAD001 AZD1480 RAD001 AZD1480
15610 1962 2.962 2.561 0.61±0.2
RAD001 Ruxolitinib RAD001 Ruxolitinib
15610 1.861 1.9 0.2 0.26
PP242 AZD1480 PP242 AZD1480
160.7 1962 0.04 0.7 0.13
PP242 Ruxolitinib PP242 Ruxolitinib
160.7 1.861 0.1660.1 0.360.2 0.5±0.3
Data shown (mean 6 SD) are derived from the analysis of two patients, in
duplicate. The Combination Index (CI) was calculated as described in Materials
and Methods. A CI,1 indicates that the interaction of the two drugs is
synergistic. The first two columns (in gray) report, for convenience, the IC50
value of the individual drugs in this experimental setting (see Results section for
details).
doi:10.1371/journal.pone.0054826.t004
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scenario, makes it an attractive target for therapy in neoplasia
where involvement of the mTOR pathway contributes to disease
pathogenesis; activation of this pathway has been demonstrated in
MPN cells [29,30], JAK2V617F-expressing mice [19] [38] and
primary samples [41,43]. However, in most trials performed in
different clinical settings [55] RAD001 and other rapalogs resulted
in disease stabilization rather than tumor regression, an effect
largely attributable to the predominantly cytostatic effect of these
agents. Indeed, in a mouse myeloproliferative disease model
characterized by constitutively active STAT5, treatment with
rapamycin effectively reduced myeloid cell proliferation in
transplanted mice and significantly prolonged survival; however,
the myeloproliferative disease recurred once the treatment was
stopped [56]. Such prevalent antiproliferative rather than pro-
apoptotic effect of rapamycin derivatives including RAD001 has
prompted on one side studies of combination with agents that
preferentially induce apoptosis or are directed against other
disease-associated targets [55] on the other the development of
novel ATP-competitive mTOR inhibitors or dual PI3K/mTOR
inhibitors. Bearing this in mind, we explored the effects of
combining mTOR and JAK1/JAK2 inhibitors in vitro. We first
determined that, in the same experimental settings, JAK2
inhibitors (AZD1480 [44] and Ruxolitinib [21]) efficaciously
impaired the growth of JAK2V617F mutated mouse and human
cell lines and primary cells by slowing the progression to S-phase
of the cell cycle and exerting a more definite apoptotic effect, at
least in part mediated by downregulation of BcLxL and PIM.
Accordingly, we determined that combination of mTOR and
JAK2 inhibitor resulted in significant synergism concerning the
inhibition of proliferation and colony formation of mouse and
human JAK2V617 mutated leukemia cell lines and prevented at
very low nanomolar concentration the formation of EPO-
independent erythroid colonies.
Combinations of mTOR inhibitor with chemotherapeutics,
targeted drugs or antibodies are being explored in preclinical
models and/or have been preliminary reported in clinical trials. At
this regard, combination of rapamycin with ABT-737, an inhibitor
of Bcl-XL, has recently been shown to provoke synergistic effects in
mice with a myeloproliferative disorder due to constitutively active
STAT5 and persistent activation of Akt/mTOR signalling [57].
Present data describing synergistic activity of mTOR- and JAK/
STAT-directed therapies in cellular models of MPN foresee the
opportunity of testing this association in clinical trials, with the
expectation that such combination might results in a better
therapeutic index producing more effective inhibition of clonal
cells and also, due to the modest toxicity of mTOR inhibitors
against normal cells, by reducing unwanted side effects of JAK2
inhibitors administered at lower, yet effective, dose.
Supporting Information
Figure S1 Effect of different amount of EPO added to
the culture medium of Ba/F3-EPOR wild-type cells on
the level of phosphorylated STAT5. In order to determine
the optimal amount of EPO that induced phosphorylation of
STAT5 in Ba/F3-EPOR wild-type (wt) cells at level comparable
with JAK2V617F (VF) mutated cells, we added different amounts
of EPO and then processed the cells for western blot analysis after
6 h. Each phosphoSTAT5 band was first normalized by
densitometric analysis using the ImageQuant 350 apparatus (GE
Healthcare, Little Chalfont, UK) and the ImageQuant 5.2
software against corresponding total STAT5, then the values
measured in wt cells were normalized against the level measured in
VF cells considered as = 1. The amount of phosphoSTAT5 in the
presence of 1 U/mL Epo was 1.2, close to VF cells.
(TIF)
Figure S2 Effect of mTOR (RAD001 and PP242) and
JAK2 (AZD1480 and Ruxolitinib) inhibitors on apoptosis
and cell cycle in Ba/F3-EPOR VF cells. In panel A, the
frequency of cells in the G0/G1, S and M phase of the cell cycle
was measured by flow cytometry after propidium iodide staining of
Ba/F3-EPOR VF cells that had been exposed to the drugs for
18 h, and expressed as percent change compared to control cells
(Ctrl) with vehicle. Results shown are the Mean6SD of at least
three experiments. In panel B, the percentage of Annexin V-
positive cells was measured in cultures of Ba/F3-EPOR VF cells
exposed to varying amount of the drugs for 48 h; percentage was
calculated after subtraction of background apoptosis in cells
incubated without drug. Results shown are the Mean6SD of at
least three experiments.
(TIF)
Figure S3 Effect of mTOR (RAD001 and PP242) and
JAK2 (AZD1480 and Ruxolitinib) inhibitors on key
targets in Ba/F3-EPOR VF and SET-2 cells. A. JAK2 wt
and VF Ba/F3-EPOR cells were incubated for 6 h with final
concentrations of the drugs corresponding to the IC50 values
measured in proliferation assay (see Results for details). B. SET-2
cells were incubated for 24 h with increasing concentrations of the
drugs, as indicated. The level of total and phosphorylated JAK2,
STAT5, and 4EBP1 was analyzed by western blot. Tubulin was
used for loading normalization. One representative of two to four
similar experiments.
(TIF)
Figure S4 Effect of mTOR (RAD001 and PP242) and
JAK2 (AZD1480 and Ruxolitinib) inhibitors on the
expression of selected downstream molecules in SET-2
cells. The expression level of mRNA for PIM1, BCLxL and
CCND1 was measured by RTQ-PCR in SET-2 cells at different
times of incubation with the IC50 concentration of each drug, in
triplicate. Gene expression profiling was achieved using the
Comparative cycle threshold (CT) method of relative quantitation
using VIC-labeled RNaseP probe as PIM1the housekeeping gene
(DCT). Where not indicated, SD was,10% for each experimental
point and was not depicted. This experiment has been repeated
twice with similar results. *, P,0.05; **, P,0.01.
(TIF)
Figure S5 Analysis of the combinatory effects of mTOR
(RAD001 and PP242) and JAK2 (AZD1480 and Ruxoliti-
nib) inhibitors in Ba/F3-EPOR VF cells. Cells were
evaluated in proliferation assay for 48 h using WST-1 assay to
measure the proportion of cells alive, after subtraction of the value
measured in control wells with vehicle only. ‘‘Fa’’ is the cell
fraction affected by the dose of the drug; the combination Index
(CI) was calculated as described in Materials and Methods using
Calcusyn Software. A CI,1 indicates that the interaction of the
two drugs is synergistic.
(TIF)
Figure S6 Analysis of the combinatory effects of the
mTOR (RAD001 and PP242) and JAK2 (AZD1480 and
Ruxolitinib) inhibitors in SET-2 cells. Cells were evaluated
in proliferation assay for 48 h using WST-1 assay to measure the
proportion of cells alive, after subtraction of the value measured in
control wells with vehicle only. ‘‘Fa’’ is the cell fraction affected by
the dose of the drug; the combination Index (CI) was calculated as
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described in Materials and Methods using Calcusyn Software. A
CI,1 indicates that the interaction of the two drugs is synergistic.
(TIF)
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